MARKET

WVE

WVE

Wave Life Scienc
NASDAQ
5.71
-0.28
-4.67%
After Hours: 5.71 0 0.00% 16:18 06/18 EDT
OPEN
5.95
PREV CLOSE
5.99
HIGH
6.02
LOW
5.69
VOLUME
380.02K
TURNOVER
0
52 WEEK HIGH
7.67
52 WEEK LOW
3.450
MARKET CAP
699.25M
P/E (TTM)
-10.8658
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at WVE last week (0610-0614)?
Weekly Report · 1d ago
WAVE LIFE SCIENCES ANNOUNCES UPCOMING PRESENTATIONS HIGHLIGHTING NOVEL SIRNA PROGRAM IN OBESITY AND LEADERSHIP IN RNA EDITING
Reuters · 6d ago
Truist Financial Gives a Buy Rating to Wave Life Sciences (WVE)
TipRanks · 06/11 11:26
Weekly Report: what happened at WVE last week (0603-0607)?
Weekly Report · 06/10 09:48
Alnylam, Pliant among stocks yet to face Q2 catalysts: Wells Fargo
Wells Fargo highlighted the remaining biotech catalysts scheduled for Q2 2024. Alnylam Pharmaceuticals, Pliant among stocks yet to face Q2 catalysts. The company is set to release topline data from a Phase 3 trial in late June or early July.
Seeking Alpha · 06/07 19:09
Weekly Report: what happened at WVE last week (0527-0531)?
Weekly Report · 06/03 09:48
Weekly Report: what happened at WVE last week (0520-0524)?
Weekly Report · 05/27 09:50
PTC Therapeutics rallies 18% on EU authorization update for Translarna
PTC Therapeutics rallies 18% on EU authorization update for Translarna. The company announced the European Commission is allowing its Duchenne muscular dystrophy therapy to remain on the market in Europe. PTC's stock rallied 18% early Monday after the announcement.
Seeking Alpha · 05/20 13:58
More
About WVE
Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).

Webull offers Wave Life Sciences Ltd stock information, including NASDAQ: WVE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, WVE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading WVE stock methods without spending real money on the virtual paper trading platform.